Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials
Open accessThe DOI matches its Crossref record; 129 of the 137 references it cites were found in a registry or an index; 14 of the 57 sources its claims cite were checked for support.
Abstract
BACKGROUND: Findings of substantial remaining morbidity in treated major depressive disorder (MDD) led us to review controlled trials of treatments aimed at preventing early relapses or later recurrences in adults diagnosed with MDD to summarize available data and to guide further research. METHODS: Reports (n = 97) were identified through systematic, computerized literature searching up to February 2015. Treatment versus control outcomes were summarized by random-effects meta-analyses. RESULTS: In 45 reports of 72 trials (n = 14 450 subjects) lasting 33.4 weeks, antidepressants were more effective than placebos in preventing relapses (response rates [RR] = 1.90, confidence interval [CI]: 1.73-2.08; NNT = 4.4; p < 0.0001). In 35 reports of 37 trials (n = 7253) lasting 27.0 months, antidepressants were effective in preventing recurrences (RR = 2.03, CI 1.80-2.28; NNT = 3.8; p < 0.0001), with minor differences among drug types. In 17 reports of 22 trials (n = 1 969) lasting 23.7 months, psychosocial interventions yielded inconsistent or inconclusive results. CONCLUSIONS: Despite evidence of the efficacy of drug treatment compared to placebos or other controls, the findings further underscore the substantial, unresolved morbidity in treated MDD patients and strongly encourage further evaluations of specific, improved individual and combination therapies (pharmacological and psychological) conducted over longer times, as well as identifying clinical predictors of positive or unfavorable responses and of intolerability of long-term treatments in MDD.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis found that antidepressants significantly reduce relapse and recurrence in adults with major depressive disorder compared with placebo, with long-term maintenance treatment showing the largest pooled effect. Psychosocial interventions yielded inconsistent and generally weaker evidence, though some benefit appeared in patients with multiple prior episodes.
Key findings
- In 45 reports of 72 continuation trials (n = 14,450; mean 8.35 months), antidepressants were more effective than placebo in preventing relapse: RR = 1.90 (95% CI 1.73–2.08), NNT = 4.4 (3.8–5.2), p < 0.0001; relapse risk averaged 23.3% with continued antidepressant vs 49.4% after discontinuation.
- In 35 reports of 37 long-term trials (n = 7,253; mean 26.8 months), antidepressants were effective in preventing recurrence: RR = 2.03 (95% CI 1.80–2.28), NNT = 3.8 (3.3–4.6), p < 0.0001; 32/37 (86.5%) trials showed significant superiority of active drug over control.
- In 17 reports of 22 psychosocial trials (n = 1,969; mean 23.7 months), pooled RR = 1.39 (95% CI 1.13–1.70), NNT = 6.0 (3.8–14), p = 0.002, but 11/22 (50.0%) comparisons were nonsignificant; benefit was greater in patients with high prior recurrences (RR = 1.63, 95% CI 1.04–2.57) than low prior recurrences (RR = 0.80, 95% CI 0.58–1.09).
- Meta-regression found longer initial treatment before randomization was associated with larger drug–placebo contrast in continuation trials (β = +0.048, CI 0.024–0.073, p < 0.001), and longer long-term treatment duration was associated with larger drug–placebo contrast in maintenance trials (β = +0.104, CI 0.044–0.163, p < 0.001).
Methods
- Systematic review and random-effects meta-analysis of controlled trials identified through computerized searches of PubMed/Medline, Scieverse, SciDirect, and Web-of-Science up to February 2015; 803 reports screened, 146 reviewed in detail, and 97 reports included.
- Inclusion required adults with major depressive disorder, English-language reports, and examination of relapse or recurrence with pharmacological or non-pharmacological treatment; exclusions were bipolar depression, seasonal depression, juvenile depression, and studies only of adverse events or costs.
- Two investigators independently extracted data; analyses computed relative response rates (RRs), rate differences, and number-needed-to-treat (NNT), with meta-regression testing covariates including trial year, size, age, sex proportion, prior episodes, initial treatment weeks, trial duration, and antidepressant type.
Limitations
- Stated by the paper: few well-designed non-pharmacological or combination-treatment studies; follow-up periods ranged from several months to five years (average up to 2 years), with actual times to new episodes usually not reported; many trials used “enriched” designs requiring short-term response, limiting generalizability; many trials discontinued active treatment in barely recovered patients, possibly contributing to inferior placebo outcomes; juvenile and mainly geriatric depression were excluded; some placebo arms were reused in multi-arm trials, though sensitivity analyses showed minor effects; and many studies lacked clinical details on prior episodes, subjective wellness, functioning, and predictors of tolerability or response.
- Evident from the text: psychosocial trials were heterogeneous and half of comparisons were nonsignificant, making conclusions about psychosocial maintenance treatment less secure than those for antidepressants.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Findings from random-effects meta-analysis of 37 controlled, long-term trials (>12 months) of antidepressants vs. placebos in major depression. The pooled ratio (RR) of recurrence risk with placebo vs. antidepressants, of 2.03 [CI: 1.80-2.28]) is highly significant (z-score = 11.7, p < 0.0001).](https://figures.cochat.ai/paper-figures/aeb112a55a4446f3aa7a4372000f0d00/prevention-of-relapse-and-recurrence-in-adults-with-major-depressive-disorder-figure-2.jpg)
Verification
Claims the paper makes
10 Valid · 1 Not valid · 20 Not checked · 55 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Their findings favored ECT added or compared with medicinal treatments (Gagne et al., 2000; Kellner et al., 2006).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Not checked — no full text of the sourcecites Gagne et al., 2000 source
- Disputedcites Kellner et al., 2006 sourceExperimental — accuracy not yet measured
The EFFICACY RESULTS section (page not provided) reports no statistically significant difference between continuation ECT and pharmacotherapy; relapse was 37.1% with ECT versus 31.6% with pharmacotherapy. The COMMENT section likewise says there was no statistical evidence that either treatment had greater efficacy. This study therefore does not support a finding favoring ECT over medication. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Family psychoeducation appeared to be useful long-term in two studies reported from Japan (Shimazu et al., 2011; Shimodera et al., 2012).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion
What the sources say
- Supportedcites Shimazu et al., 2011 source
The Method section identifies this as a study conducted in Japan. The Discussion reports that family psychoeducation significantly reduced relapse of major depression for up to nine months, supporting its usefulness over the study’s follow-up period. This citation accounts for one of the two studies named in the citing sentence. (LLM, conf=0.91)
- Partly supportedcites Shimodera et al., 2012 sourceExperimental — accuracy not yet measured
The Results > Clinical outcomes section reports fewer relapses and more relapse-free days with family psychoeducation during nine months of follow-up in this Japanese trial. But the Discussion explicitly says whether its preventive effect lasts beyond nine months is unknown, so the source does not establish long-term usefulness. This verdict addresses Shimodera et al. only, not the other study cited in the sentence; our copy provides no page numbers. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 3 assumptions not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These failed trials involved antidepressants such as tricyclic antidepressants (Maj et al., 1992), SSRIs (Wilson et al., 2003; Reynolds et al., 2006), the anxiolytic SNRI milnacipran (Rouillon et al., 2000), and a preparation of the plant Hypericum perforatum (St. John’s Wort; Kasper et al., 2008).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Long-Term Antidepressant Treatment
What the sources say
- Not matchedcites Maj et al., 1992
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Wilson et al., 2003 source
The citation to Wilson et al. (2003) is attached to the SSRI example, not to the other drug classes or the count of five trials. In “Analysis of recurrence” (page unavailable), the paper reports no significant difference between sertraline and placebo in preventing recurrence during maintenance treatment. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites Reynolds et al., 2006 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 4 assumptions not shown here.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these, notably, family psychoeducation continued for up to 10 months was examined in two Japanese studies and found to be clinically effective and cost-effective in reducing recurrence risks in major depressive disorder patients (Shimazu et al., 2011; Shimodera et al., 2012).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Partly supportedcites Shimazu et al., 2011 sourceExperimental — accuracy not yet measured
The Discussion reports that four sessions of family psychoeducation significantly reduced relapse compared with treatment as usual, supporting clinical effectiveness. But the Family psychoeducation section says sessions occurred every two weeks, and the Discussion reports outcomes for up to 9 months; the intervention did not continue for up to 10 months. (LLM, conf=0.90)
- Partly supportedcites Shimodera et al., 2012 sourceExperimental — accuracy not yet measured
The Results > Clinical outcomes report fewer relapses with family psychoeducation than with treatment as usual over nine months (2 versus 15). But Methods > Procedure describes four sessions held every two weeks, not psychoeducation continued for up to 10 months; nine months was the follow-up period. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several trials of this treatment method did not provide superior protection against recurrences of depression than control conditions (Kuyken et al., 2008; Bondolfi et al., 2010; Mathew et al., 2010).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Discussion > Non-Pharmacological Treatments
What the sources say
- Not checked — no full text of the sourcecites Kuyken et al., 2008 source
- Partly supportedcites Bondolfi et al., 2010 sourceExperimental — accuracy not yet measured
The Results report similar relapse rates over 14 months for MBCT plus treatment as usual and treatment as usual alone (29% versus 34% in the intention-to-treat sample), supporting the claim that this trial did not show fewer recurrences. But relapse occurred significantly later among MBCT participants who relapsed, so the unqualified statement that it provided no superior protection omits a benefit the paper reports. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Mathew et al., 2010 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
51 more claims · 3 with their cited sources checked
Create a free account to see all 86 claims and every source verdict.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sim et al. included various types of maintenance therapy such as antidepressant monotherapy, polypharmacy, combination therapy (e.g., antidepressants plus psychotherapy, electroconvulsive therapy, and lithium) regardless of whether a study continued the same antidepressant used for acute treatment in the maintenance phase or switched to a new one.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, a meta-analysis by Sim et al. showed that 6 of the 15 studies submitted to the FDA by Borges et al. had the same number of subjects as the other published studies included in their meta-analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, they used the data from Borges et al.’s study which risks the possibility of duplicate analysis.”
From Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in agreement with clinical studies showing that remitted patients treated with fluoxetine present higher rates of relapse, in comparison with other ADs.30, 31”
From Adult hippocampal neuroplasticity triggers susceptibility to recurrent depression (2017) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most trials recruited patients with depression from specialist mental health services, treated them with antidepressants for 3 to 8 months, and randomly assigned patients who had a response to therapy to continue antidepressant therapy or switch to placebo.”
From Maintenance or Discontinuation of Antidepressants in Primary Care (2021) · cites this paper as [9]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Consistentz = 11.7reported p < .0001 · recomputed p < .001
“(z=11.7, p < .0001”
- Consistentz = 11.7reported p < .0001 · recomputed p < .001
“z = 11.7, p < .0001”
- Consistentz = 3.15reported p = .002 · recomputed p = .002
“(z = 3.15, p = .002”
- Consistentz = 2.14reported p = .03 · recomputed p = .032
“z = 2.14, p = .03”
- Consistentz = 1.41reported p = .16 · recomputed p = .159
“z = 1.41, p = .16”
2 more recomputed tests
Create a free account to see every test the Stats check recomputed.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Psychosocial Treatments
“Ma & Teasdale, 2004 a | 38 | MCT (high) | TAU | 0.98 (0.68–1.26)”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Psychosocial Treatments
“1.4 (1.1–1.9)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Effect of Type of Treatment
“Only TCAs (n = 10) and the pool of SSRIs (n = 11) and SNRIs (n = 7) provided at least 10 trials for meta-analysis, and all yielded similar RR values (2.09, 2.10, and 2.17, respectively).”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Effect of Type of Treatment
“SSRIs (2.17) ≥ SNRIs (2.10) ≥ TCAs (2.09)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
“b, long-term antidepressants (2.02) > a, continuation of antidepressants (1.90) > c, long-term psychosocial treatments (1.39)”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
“| RR (95% CI) | 1.90 (1.73–2.08) | 2.03 (1.80-2.28) | 1.39 (1.13–1.70) |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Per trial | 189 (138–239) | 188 (131–245) | 124 (92.1–156) |”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Summary of Findings
Reported 189 · recomputed 200.694444
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Continuation Trials of Antidepressants
“Montgomery et al., 1998 | Mirtazapine | 387 | 6.78 (3.32–13.9) | 4.2 (5.9–6.8) | 1.04”
§ Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials > Results > Continuation Trials of Antidepressants
“5.9–6.8”
Citations
Cites
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.
Teasdale, J. D., Segal, Z. V., Williams, J. M. G., Ridgeway, V. A., Soulsby, J. M., & Lau, M. A. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.4.615 · Cited by 3,236 · cited 4×
“, 2010), and others found beneficial effects among patients with at least three previous depressive episodes (Teasdale et al., 2000; Ma and Teasdale, 2004).”
BackgroundInfluentialMa, S. H., & Teasdale, J. D. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.1.31 · Cited by 1,390 · cited 10×
“Several of the studies reviewed found that treatment effects appeared to be superior among patients with multiple (especially ≥3) previous episodes of depression (Montgomery et al., 1993; Teasdale et al., 2000; Lepine et al., 2004; Ma and Teasdale, 2004; Kelin et al., 2010).”
BackgroundInfluentialThree-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“Earlier reviews and meta-analyses and recent treatment guidelines for long-term treatment of MDD are generally supportive of treatments continued for several months as well as more than a year, particularly pharmacotherapies (Geddes et al., 2003; Lam et al., 2009; Pilling et al., 2009; Williams et al., 2009; Glue et a…”
MethodMindfulness-based cognitive therapy to prevent relapse in recurrent depression.
Kuyken, W., Byford, S., Taylor, R. S., Watkins, E., Holden, E., White, K., Barrett, B., Byng, R., Evans, A., Mullan, E., et al. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0013786 · Cited by 770 · cited 2×
“Several trials of this treatment method did not provide superior protection against recurrences of depression than control conditions (Kuyken et al., 2008; Bondolfi et al., 2010; Mathew et al., 2010).”
BackgroundPrevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735 · cited 2×
“There is also some evidence that use of CBT during an index episode of acute depression may have long-lasting beneficial effects in limiting risks of relapse or recurrences for up to 2 years after initial remission (Hollon et al., 2005; Dobson et al., 2008).”
BackgroundSackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686
Reynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Research works printed but not linked: 3
- Georgotas, 1985, Affective disorders: pharmacotherapy, Compr Psychiatry, 4, 821
- 10.1176/appi.ajp.131.2.186 · doi:10.1176/appi.ajp.131.2.186
- Lendresse, 1985, Traitement prolongé par nomifensine 75mg dans les états dépressifs neurotiques et reactionnels, Psychiatrie Francaise, 16, 156
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
“A meta-analysis found significant benefit of antidepressants over placebo in maintenance studies of 1 to 12 months (72 trials, N 1⁄4 14450) and 12 months (35 trials, N 1⁄4 7253).(83) Similarly, a review of all 16 maintenance RCTs (N > 4000) submitted to the Food and Drug Administration (FDA) found a 2-fold difference…”
BackgroundMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
“Australian & New Zealand Journal of Psychiatry, 55(1) delivered during the acute phase also have benefits for the maintenance phase: effects of psychological interventions endure at 6 and 12 months (Cuijpers, 2017), and there is some evidence for maintenance of benefits at 2 years (Sim et al., 2016) after treatment ha…”
BackgroundResultInfluentialRecognizing Depression from the Microbiota–Gut–Brain Axis
Liang, S., Wu, X., Hu, X., Wang, T., & Jin, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061592 · Cited by 380
“More than 85% of patients with a first episode will relapse in the next 10 years, and most of the patients have suicidal thoughts, 15–20% of whom will die from suicide [4,5].”
BackgroundLam, R. W., McIntosh, D., Wang, J., Enns, M. W., Kolivakis, T., Michalak, E. E., Sareen, J., Song, W.-Y., Kennedy, S. H., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659416 · Cited by 288
“Clinicians should focus on healthy life strategies, personality vulnerabilities, long-term selfmanagement, and clinical strategies to reduce recurrence.(104,107) In a significant proportion of patients with MDD, maintenance pharmacological, psychological, complementary and alternative medicine, and neurostimulation tr…”
BackgroundPharmacological treatment of adult bipolar disorder
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0044-2 · Cited by 272
Self-citationAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Exercise interventions for the prevention of depression: a systematic review of meta-analyses
Hu, M. X., Turner, D., Generaal, E., Bos, D., Ikram, M. K., Ikram, M. A., Cuijpers, P., & Penninx, B. W. J. H. (2020) · BMC Public Health · doi:10.1186/s12889-020-09323-y · Cited by 233
On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?
Roohi, E., Jaafari, N., & Hashemian, F. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02100-7 · Cited by 225
“Despite available pharmacotherapeutic options, 30–60% of patients with MDD are not responsive to available treatments [5] and the rate of remission of the disease is often < 50% [6], while recurrence rates are more than 85% within 10 years of a depressive episode, and average about ≥ 50% within 6 months of assumed cli…”
BackgroundMore treatment but no less depression: The treatment-prevalence paradox
Ormel, J., Hollon, S. D., Kessler, R. C., Cuijpers, P., & Monroe, S. M. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102111 · Cited by 213
Maintenance or Discontinuation of Antidepressants in Primary Care
Lewis, G., Marston, L., Duffy, L., Freemantle, N., Gilbody, S., Hunter, R., Kendrick, T., Kessler, D., Mangin, D., King, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106356 · Cited by 192
Ren, Q., Ma, M., Ishima, T., Morisseau, C., Yang, J., Wagner, K. M., Zhang, J.-C., Yang, C., Yao, W., Dong, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601532113 · Cited by 162
Wang, J., Zhang, Y., Chen, Y., Wang, Y., Li, S., Wang, Y., ZHANG, Z.-X., Zhang, J., & Rong, P. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02341-6 · Cited by 175
“While about 40% of patients have residual symptoms after drug withdrawal and the recurrence rate for depression is 85% within 10 years [6].”
Backgroundon behalf of the RADAR-CNS consortium, Matcham, F., Barattieri di San Pietro, C., Bulgari, V., de Girolamo, G., Dobson, R., Eriksson, H., Folarin, A. A., Haro, J. M., Kerz, M., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2049-z · Cited by 152
“Predictors of depressive relapse include disrupted sleep (9), reduced sociability (10), changes in mood (11), prosody (12) and cognition (13), and there is evidence highlighting the impact psychological and pharmacological interventions can have on reducing risk of relapse (14,15).”
BackgroundKato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
“There are two other meta-analyses conducted recently [4, 12], but they included various interventions and pooled heterogeneous designs together without considerations to it.”
Furukawa, T. A., Shinohara, K., Sahker, E., Karyotaki, E., Miguel, C., Ciharova, M., Bockting, C. L. H., Breedvelt, J. J. F., Tajika, A., Imai, H., et al. (2021) · World Psychiatry · doi:10.1002/wps.20906 · Cited by 126
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
“Moreover, the previous pairwise metaanalyses for individuals with MDD in the maintenance phase did not evaluate the risk of individual adverse events of antidepressants [7, 10, 11].”
BackgroundMalhi, G. S., Bell, E., Singh, A., Bassett, D. L., Berk, M., Boyce, P. M., Bryant, R. A., Gitlin, M. J., Hamilton, A., Hazell, P., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.13035 · Cited by 131
Zhang, J., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Wu, J., Ushida, Y., Suganuma, H., et al. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.10.004 · Cited by 116
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108
Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement
Stute, P., Spyropoulou, A. C., Karageorgiou, V., Cano, A., Bitzer, J., Ceauşu, I., Chedraui, P. A., Durmuşoğlu, F., Erkkola, R. U., Goulis, D. G., et al. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.11.002 · Cited by 110
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93
Strategies to reduce use of antidepressants
Kendrick, T. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14475 · Cited by 96
“pressants are appropriate for some patients to reduce the risk of relapse.(26,27) The National Institute for Health and Care Excellence (NICE) recommends treating people for 2 years in the first instance if”
BackgroundRole of Soluble Epoxide Hydrolase in Metabolism of PUFAs in Psychiatric and Neurological Disorders
Hashimoto, K. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00036 · Cited by 100
McGovern, A. S., Hamlin, A. S., & Winter, G. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419877954 · Cited by 89
“%) relapse even with continuing treatment (Rush et al., 2006; Sim et al., 2015).”
BackgroundYasin, S., Othmani, A., Raza, I., & Hussain, S. A. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.106741 · Cited by 103
Ketamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Adult hippocampal neuroplasticity triggers susceptibility to recurrent depression
Alves, N. D., Correia, J. S., Patrício, P., Mateus-Pinheiro, A., Machado-Santos, A. R., Loureiro-Campos, E., Morais, M., Bessa, J. M., Sousa, N., & Pinto, L. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.29 · Cited by 79
Sakurai, H., Suzuki, T., Yoshimura, K., Mimura, M., & Uchida, H. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4634-5 · Cited by 93
“Depression is a serious, frequently recurrent illness as a significant proportion of patients experience relapse following an initial improvement or even remission (Georgotas et al. 1989, Sim et al. 2015).”
InfluentialLate-Life Depression, Cognitive Impairment, and Relationship with Alzheimer’s Disease
Invernizzi, S., Simoes Loureiro, I., Kandana Arachchige, K. G., & Lefebvre, L. (2021) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000519453 · Cited by 80
Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment
Tondo, L., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0715-0 · Cited by 71
Self-citationAntisuicidal Effects in Mood Disorders: Are They Unique to Lithium?
Tondo, L., & Baldessarini, R. (2018) · Pharmacopsychiatry · doi:10.1055/a-0596-7853 · Cited by 69
Self-citationGlutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“In patients who do achieve relief of depression symptoms, between 25 and 60% experience recurrence of depression [22, 23].”
BackgroundMorbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
Self-citationPathogenesis of depression and the potential for traditional Chinese medicine treatment
Ding, W., Wang, L., Li, L., Li, H., Wu, J., Zhang, J., & Wang, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1407869 · Cited by 69
Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders
Törnblom, H., & Drossman, D. A. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0664-3 · Cited by 73
QbD-driven development of intranasal lipid nanoparticles for depression treatment
Vitorino, C., Silva, S., Gouveia, F., Bicker, J., Falcão, A. C., & Fortuna, A. C. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.04.011 · Cited by 60
Economides, M., Ranta, K., Nazander, A., Hilgert, O., Goldin, P. R., Raevuori, A., & Forman-Hoffman, V. (2019) · JMIR mHealth and uHealth · doi:10.2196/14284 · Cited by 56
“This is important because an estimated 50% or more of patients with major depression or generalized anxiety disorder will relapse within 6 to 12 months after the end of an initially effective treatment [30-32].”
Prevalence and predictors of probable depression in prostate cancer survivors
Erim, D., Bensen, J. T., Mohler, J. L., Fontham, E. T. H., Song, L., Farnan, L., Delacroix, S. E., Peters, E. S., Erim, T. N., Chen, R. C., et al. (2019) · Cancer · doi:10.1002/cncr.32338 · Cited by 64
Updates on the Role of Probiotics against Different Health Issues: Focus on Lactobacillus
Un-Nisa, A., Khan, A., Zakria, M., Siraj, S., Ullah, S., Tipu, M. K., Ikram, M. A., & Kim, M. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010142 · Cited by 69
“Depression is a serious, recurring, lethal, and debilitating neuropsychological disorder [110,111], characterized by loss of interest, low mood, feeling of guilt, hopelessness, change in sleep and appetite, sexual dysfunction, etc.”
BackgroundHengartner, M. P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00275 · Cited by 52
“Meta-analyses of discontinuation trials suggest that long-term antidepressant use may prevent relapse, but only very few trials have empirically examined that effect for 2 years or more (56, 57).”
BackgroundResultSubbaiah, M. A. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01827 · Cited by 56
Korean Medication Algorithm for Depressive Disorders 2017: Third Revision
Seo, J. S., Bahk, W., Wang, H. R., Woo, Y. S., Park, Y. M., Jeong, J., Kim, W. K., Shim, S.-H., Lee, J. G., Jon, D., et al. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.1.67 · Cited by 48
Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses
Yee, C. S., Hawken, E. R., Baldessarini, R. J., & Vázquez, G. H. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz034 · Cited by 46
“, 2019) as well as in major depressive disorder (Sim et al., 2015) and can be carried out in jBD as well (Strober et al.”
BackgroundResultSelf-citationAntidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges
Vitorino, C., Silva, S., Bicker, J., Falcão, A. C., & Fortuna, A. C. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.001 · Cited by 48
Zhang, J.-C., Yao, W., Qu, Y., Nakamura, M., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., Shirayama, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07325-2 · Cited by 50
Hallford, D. J., Austin, D., Takano, K., Fuller‐Tyszkiewicz, M., & Raes, F. (2020) · Behaviour Research and Therapy · doi:10.1016/j.brat.2020.103783 · Cited by 35
Economic burden of relapse/recurrence in patients with major depressive disorder
Gauthier, G., Mucha, L., Shi, S., & Guerin, A. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1612410 · Cited by 36
Maffioletti, E., Minelli, A., Tardito, D., & Gennarelli, M. (2020) · Genes · doi:10.3390/genes11091089 · Cited by 39
“Recurrence rates are over 85% within a decade from an index depressive episode, and average approximately 50% or more within six months of apparent clinical remission if the initially effective treatment is not continued [2,3].”
BackgroundTRPV1 blockers as potential new treatments for psychiatric disorders
Iglesias, L. P., de Aguiar, D. C., & Moreira, F. A. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000603 · Cited by 36
“Since current pharmacological treatments still fail in efficacy and safety in various patients (Bruce et al., 2005; Sim et al., 2015), new drug targets for psychiatric disorders are warranted.”
BackgroundInhibition of IL-6 methylation by Saikosaponin C regulates neuroinflammation to alleviate depression
Bai, Z., Gao, T., Zhang, R., Lu, Y., Tian, J., Wang, T., Zhao, K., & Wang, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110043 · Cited by 37
A Computational Theory of Mindfulness Based Cognitive Therapy from the “Bayesian Brain” Perspective
Manjaly, Z., & Iglesias, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00404 · Cited by 51
Optimization of a Digital Medicine System in Psychiatry
Rohatagi, S., Profit, D., Hatch, A., Zhao, C. Y., Docherty, J. P., & Peters-Strickland, T. S. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10693 · Cited by 33
“A series of studies is being conducted to (1) identify the safety, tolerability, and usability of each individual component of the system; (2) evaluate safety and tolerability of the whole system; (3) determine human factors (HF) usability; and (4) assess integration of the individual components into the system and in…”
BackgroundSoluble epoxide hydrolase: a new therapeutic target for depression
Hashimoto, K. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1226284 · Cited by 32
Tanner, J., Davies, P. E., Overall, C. C., Grima, D. T., Nam, J., & DeChairo, B. M. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0012 · Cited by 31
Smit, A. C., Snippe, E., Bringmann, L. F., Hoenders, R. H. J., & Wichers, M. (2022) · Quality of Life Research · doi:10.1007/s11136-022-03301-0 · Cited by 36
“Though a lot of research has focused on identifying risk factors [1, 2, 5], and preventing recurrence through antidepressant maintenance treatment or preventive therapies [4, 6, 7], surprisingly little research has focused on the actual process through which depressive symptoms return.”
BackgroundExploration of GP perspectives on deprescribing antidepressants: a qualitative study
Kelly, D., Graffi, J., Noonan, M., Green, P., Mcfarland, J. W., Hayes, P., & Glynn, L. G. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046054 · Cited by 36
Smit, A. C., Snippe, E., & Wichers, M. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500594 · Cited by 27
Shinohara, K., Efthimiou, O., Ostinelli, E. G., Tomlinson, A., Geddes, J. R., Nierenberg, A. A., Ruhe, H. G., Furukawa, T. A., & Cipriani, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027574 · Cited by 27
“Once remitted from the acute phase of antidepressant therapy, should one continue the antidepressant? If yes, in view of such long-term treatment, which antidepressants, if any, would be preferred at the time of the initiation of the acute-phase treatment? Although previous systematic reviews of long-term treatment of…”
BackgroundTanguay-Sela, M., Rollins, C. P. E., Pérez, T., Qiang, V., Golden, G. M., Tunteng, J.-F., Perlman, K., Simard, J., Benrimoh, D. A., & Margolese, H. C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.041 · Cited by 35
Deletion of serine racemase confers D-serine –dependent resilience to chronic social defeat stress
Dong, C., Zhang, J., Ren, Q., Ma, M., Qu, Y., Zhang, K., Yao, W., Ishima, T., Mori, H., & Hashimoto, K. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.008 · Cited by 27
“Many patients with depression become chronically ill, with several relapses of the current episode (early return of symptoms within an expected duration of 3e12 months) or later recurrences (new episodes) following initial short-term improvement or remission (Sim et al., 2016).”
BackgroundOut-of-hospital cardiac arrest in patients with psychiatric disorders — Characteristics and outcomes
Barcella, C. A., Mohr, G. H., Kragholm, K. H., Blanche, P., Gerds, T. A., Wissenberg, M., Hansen, S. M., Ringgren, K. B., Lippert, F. K., Folke, F., et al. (2019) · Resuscitation · doi:10.1016/j.resuscitation.2019.07.008 · Cited by 26
“Nevertheless, mental disorders are often relapsing: a recurrence rate over 85% within a decade from the first episode is documented for depression and of 40-55% for anxiety disorders.(35) Moreover, in our cohort about 80% of patients classified as depressed redeemed prescriptions for antidepressants shortly before OHC…”
BackgroundCosci, F., Mansueto, G., & Fava, G. A. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779308 · Cited by 29
Breedvelt, J., Karyotaki, E., Warren, F. C., Brouwer, M. E., Jermann, F., Holländare, F., Klein, N. S., de Jonge, M., Klein, D. N., Farb, N. A. S., et al. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00178-x · Cited by 33
“Consistent with previous meta-analyses, we observed no difference in efficacy between psychological intervention types (PCT, MBCT, C-CT and CBT) 15,48–51 .”
ResultInada, K., Enomoto, M., Yamato, K., Marumoto, T., Takeshima, M., & Mishima, K. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.040 · Cited by 26
Duan‐Porter, W., Goldstein, K. M., McDuffie, J. R., Hughes, J. M., Clowse, M. E. B., Klap, R. S., Masilamani, V., LaPointe, N. M. A., Nagi, A., Gierisch, J. M., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2877 · Cited by 26
Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations
Cosci, F., Guidi, J., Mansueto, G., & Fava, G. A. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1804870 · Cited by 31
Krijnen-de Bruin, E., Scholten, W., Muntingh, A., Maarsingh, O., van Meijel, B., van Straten, A., & Batelaan, N. (2022) · PLOS ONE · doi:10.1371/journal.pone.0272200 · Cited by 23
“Third, more research is needed on effective relapse prevention interventions combined with discontinuation of ADM, as most patients have reservations about the long-term use of medication [98], even though the risk of relapse during discontinuation is high [37].”
BackgroundSevere, J., Greden, J. F., & Reddy, P. (2020) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200008 · Cited by 30
Hengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
The antidepressant standoff: Why it continues and how to resolve it
Ormel, J., Spinhoven, P., de Vries, Y. A., Cramer, A. O. J., Siegle, G. J., Bockting, C. L. H., & Hollon, S. D. (2020) · Psychological Medicine · doi:10.1017/s0033291719003295 · Cited by 22
“Critics of ADMs often advocate psychological treatments, especially cognitive behavioral therapy (CBT), interpersonal therapy (IPT), mindfulness-based cognitive therapy (MBCT), and problem-solving therapy (PST).”
InfluentialKumagai, N., Tajika, A., Hasegawa, A., Kawanishi, N., Horikoshi, M., Shimodera, S., Kurata, K., Chino, B., & Furukawa, T. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2382-2 · Cited by 20
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT
Duffy, L., Clarke, C. S., Lewis, G., Marston, L., Freemantle, N., Gilbody, S. M., Hunter, R. M., Kendrick, T., Kessler, D. S., King, M., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25690 · Cited by 27
“Single 35/238 (15) 26/240 (11) Separated or divorced 39/238 (16) 33/240 (14) Widowed 18/238 (8) 20/240 (8) Employment status, n/N (%) Employed 140/238 (59) 152/240 (63) Retired 71/238 (30) 68/240 (28) Other 27/238 (11) 20/240 (8) Site, n/N (%) London 101/238 (42) 98/240 (41) Bristol 48/238 (20) 54/240 (23) Southampton…”
Touya, M., Lawrence, D. F., Kangethe, A., Chrones, L., Evangelatos, T., & Polson, M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03793-7 · Cited by 21
“In one study, the median time to recurrence was approximately 40 months in patients continuing therapy, compared with a little over 1 year in patients who discontinued antidepressant therapy [6].”
BackgroundResultInfluentialMirjebreili, S. M., Shalbaf, R., & Shalbaf, A. (2024) · Physical and Engineering Sciences in Medicine · doi:10.1007/s13246-024-01392-2 · Cited by 23
“Considering that MDD is often a relapsing disorder, it is essential to provide treatment that will maximize the patient’s chances of recovery and maintenance [1, 6, 7].”
Nuggerud-Galeas, S., Suescun, L. S.-B., Torrijo, N. B., Suescun, A. S.-B., Aguilar‐Latorre, A., Botaya, R. M., & Oliván‐Blázquez, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233454 · Cited by 26
“0001), but no significant differences were observed regarding the different treatments analyzed [33].”
BackgroundDoes food insecurity cause anxiety and depression? Evidence from the changing cost of living study
Bateson, M., Chevallier, C., Johnson, E., Johnson, M., Pickett, K. E., & Nettle, D. (2025) · PLOS mental health. · doi:10.1371/journal.pmen.0000320 · Cited by 27
“Although an imperfect comparison, an NNT of 5 has been calculated for antidepressant drugs preventing relapse of major depressive disorder [40].”
Patients' experiences of cognitive functioning in recurrent depression: A qualitative study
Crowe, M., Porter, R., Douglas, K. M., Inder, M., Lacey, C. J., Jordan, J., & Wells, H. L. (2020) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12603 · Cited by 27
More Treatment, but Not Less Anxiety and Mood Disorders: Why? Seven Hypotheses and Their Evaluation
Ormel, J., & Emmelkamp, P. M. G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000528544 · Cited by 23
Baldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 20
“Most long-term antidepressant trials do not even comment on suicidal events, and those that do appear to consider them as passively acquired, incidental examples of adverse events (Sim et al., 2015; Baldessarini et al., 2016).”
BackgroundSelf-citationAntos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
Förster, K., Kurtz, M., Konrad, A. C., & Kanske, P. (2022) · Zeitschrift für Klinische Psychologie und Psychotherapie · doi:10.1026/1616-3443/a000648 · Cited by 24
Psychopharmacologic Therapies for Irritable Bowel Syndrome
Törnblom, H., & Drossman, D. A. (2021) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2021.04.005 · Cited by 19
Ma, C., Zhang, F., Zhao, X., Yang, Y., Wang, B., Wang, Y., Liu, X.-F., Bian, X., Xu, Z., Zhang, G., et al. (2025) · Current Research in Food Science · doi:10.1016/j.crfs.2025.101020 · Cited by 17
“Its symptoms include negative thinking, lack of pleasure, anxiety and irritability, inattention, abnormal appetite, and self-destructive tendency (Sim et al., 2015).”
Yang, L., Yang, X., Yang, T., Wu, X., Sun, P., Zhu, Y., Su, Y., Gu, W., Qiu, H. X., Wang, J., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114205 · Cited by 17
(2024) · doi:10.1016/j.psychres.2024.115926 · Cited by 15
Hu, D., & Tamir, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.027 · Cited by 18
Wang, J., Liu, Y., Li, L., Qi, Y., Zhang, Y., Li, L., Teng, L., & Wang, D. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7261 · Cited by 15
“Depression, a debilitating mental disorder, is a leading cause of disability worldwide (1), and ~350 million people currently suffer from depression (2).”
Pahlevan, T., Ung, C., & Segal, Z. V. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720904613 · Cited by 17
Chambergo‐Michilot, D., Brañez‐Condorena, A., Falvy-Bockos, I., Pacheco‐Mendoza, J., & Benites-Zapata, V. A. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113652 · Cited by 16
Thesing, C. S., Lok, A., Milaneschi, Y., Assies, J., Bockting, C., Figueroa, C. A., Giltay, E. J., Penninx, B. W. J. H., Ruhé, H. G., Schene, A. H., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13136 · Cited by 17
“Major depressive disorder (MDD) is an important mental health issue with a high prevalence and recurrence rate (1).”
BackgroundInfluentialZhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 14
Kunkels, Y. K., Smit, A. C., Minaeva, O., Snippe, E., George, S. V., van Roon, A. M., Wichers, M., & Riese, H. (2023) · Clinical Psychological Science · doi:10.1177/21677026221148101 · Cited by 18
Berwian, I. M., Wenzel, J. G., Kuehn, L., Schnuerer, I., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-13893-9 · Cited by 13
Lasting scars: The impact of depression in early adulthood on subsequent labor market outcomes
Wang, B., Frank, R. G., & Glied, S. (2023) · Health Economics · doi:10.1002/hec.4747 · Cited by 20
Identification of Signs of Depression Relapse using Audio-visual Cues: A Preliminary Study
Muzammel, M., Othmani, A., Mukherjee, H., & Salam, H. (2021) · Proceedings - IEEE Symposium on Computer-Based Medical Systems · doi:10.1109/cbms52027.2021.00018 · Cited by 15
Robberegt, S. J., Kooiman, B., Albers, C. J., Nauta, M. H., Bockting, C., & Stikkelbroek, Y. A. J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058560 · Cited by 13
Zhang, X., Wang, X., Dong, D., Sun, X., Zhong, X., Xiong, G., Cheng, C., Lei, H., Chai, Y., Yu, M., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.09.003 · Cited by 11
America’s Continuing Struggle with Mental Illnesses: Economic Considerations
Frank, R. G., & Glied, S. (2023) · The Journal of Economic Perspectives · doi:10.1257/jep.37.2.153 · Cited by 17
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Metadata
- Authors
- Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sim, Kang
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-07
- Volume
- 19
- Issue
- 2
- Pages
- pyv076
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4772815
- OpenAlex
- W1913659607
- Semantic Scholar
- cbb9e5ab88cd7ec19a0140daf20022efa2e38311
- Cited by
- 218
- References
- 137
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 22 · 2023: 20 · 2022: 23 · 2021: 38 · 2020: 34 · 2019: 20 · 2018: 10 · 2017: 10 · 2016: 12 · 2015: 1
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Bruce J. Anderson Foundation
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- major depressive disorder, relapse prevention, recurrence prevention, antidepressants, psychosocial interventions, long-term treatment, predictors of treatment response, residual depressive symptoms
- MeSH terms
- Antidepressive Agents, Combined Modality Therapy, Major Depressive Disorder, Humans, Psychotherapy, Recurrence, Controlled Clinical Trials as Topic, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.